BNT327, a next-generation bispecific antibody candidate, targets PD-L1 and VEGF-A. Per the terms, BMY will make an upfront ...

DataM Intelligence | competitive Intelligence NF1 drug development accelerates with novel treatments aiming to surpass current MEK inhibito ...

NEW YORK, June 1, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS ...

Detailed price information for Springworks Therapeutics Inc (SWTX-Q) from The Globe and Mail including charting and trades.

The most significant recent development for SpringWorks is the agreement by Merck (NSE:PROR) KGaA to acquire the company for $47 per share, representing a total equity value of approximately $3.9 ...

Why is that? That's because big pharmaceutical powerhouse Merck KGaA had agreed to acquire SpringWorks Therapeutics for a purchase price of $47 per share, which represents an equity value of $3.9 ...

Two months after saying it was in advanced talks to acquire SpringWorks Therapeutics, Merck KGaA, Darmstadt, Germany, has announced it agreed to purchase the developer of drugs for severe rare ...

Under the agreement, Merck will pay $47 per share in cash, based on SpringWorks’ cash balance as of Dec. 31, 2024, and a 26% premium on SpringWorks’ unaffected 20-day volume-weighted average ...

Merck KGaA is building up its portfolio and pipeline with a $3.9 billion deal to acquire SpringWorks Therapeutics, a company with two FDA-approved rare tumor drugs, both of which offer the ...

Merck acquires SpringWorks for $47/share, valuing it at $3.9B, with a 26% premium over its 20-day average price. SpringWorks' rare tumor treatments will boost Merck's revenue and help expand its U ...

Germany's Merck KGaA agreed to acquire U.S. biopharmaceutical company SpringWorks Therapeutics for around $3.9 billion, in a bid to expand its oncology and rare disease business. The German life ...

Merck KGaA’s long courtship of SpringWorks Therapeutics has come to fruition as the German drugmaker has bought out the Connecticut biopharma for an equity value of $3.9 billion, the companies ...